AbbVie joins peers in Middle East with Saudi Arabia plans

AbbVie ($ABBV) is joining the rush to the Middle East with operations in Saudi Arabia. Its deal for the Arab Company for Pharmaceutical Products (Arabio) to manufacture Humira and other drugs in the kingdom is seen as a significant advance in the country's ability to manufacture biologics. AbbVie joins Pfizer ($PFE), which is building a plant there, while Sanofi ($SNY), Merck & Co. ($MRK) and others are establishing production and distribution operations throughout the Middle East. It is a region that is seen as one the emerging markets with the most potential. Story | More

Suggested Articles

Look out, diabetes market: Novo Nordisk won its FDA nod for highly anticipated Rybelsus to control blood sugar in patients with Type 2 diabetes.

Insys is in fire sale mode as part of its bankruptcy plan, and now it’s been given the go-ahead to sell the opioid that helped get it there.

GSK CEO Emma Walmsley could soon have a new title: Microsoft board member. The software giant has nominated her to its board of directors.